In humans with biopsy-confirmed NASH, administration of the FGF19 analog aldafermin induced in the microbiota a dose-dependent enrichment in Veillonella, a rare commensal microbe which correlated with changes in serum bile acid profile, mainly in terms of decreased toxic BA [84]. Here, FGF19 is linked to metabolic dysfunction-associated steatohepatitis.